Compare Organon & Co. Common Stock (OGN) vs Pinterest Inc (PINS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Pinterest Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Pinterest Inc trades at $21.75 (market cap $12.32B). The key difference: Pinterest Inc is far larger — about 3.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Pinterest Inc for 85 Days on average.
| OGN | PINS | |
|---|---|---|
Market Cap | $3.61B | $12.32B |
Volume | 1,808,049 | 10,523,209 |
Sector | Health | Media |
52-Week High | $13.81 | $35.24 |
52-Week Low | $5.70 | $15.42 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $11.03B | $12.24B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Pinterest (PINS) trades at $22.36, up 4.37% today, with strong technical momentum and bullish analyst sentiment. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue growth accelerated from $2.8B in 2022 to $4.2B in 2025, while profitability improved significantly from negative margins to 9.87% net income margin. Technical indicators show bullish momentum with the stock trading near resistance at $22.
PINS presents a compelling growth story with improving fundamentals and strong analyst support (54% buy ratings). The stock trades at a discount to the $27.93 consensus target, offering 25% upside potential. Key risks include competitive pressure in digital advertising and potential volatility from insider selling activity. The company's visual search ads innovation and international monetization growth provide catalysts for continued expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
